Rd Milestone Payments Sample Clauses
Rd Milestone Payments. (a) R& DMilestones Payments. Following termination of this Agreement, the basis for determining whether or not a particular R&D Milestone payment is due and the amount of such payment shall be the results of testing of Designated Organisms designated by GENENCOR as in Paragraph 10.5 above. To qualify for a given R&D-based Milestone payment, a Designated Organism must meet the performance standards for *** set out in Article 3 herein.
(b) Interpolation Between R&D Milestone Payments. Following termination of this Agreement for reasons other than breach by GENENCOR and if performance of at least *** of the difference between the previously met R&D Milestone target and the next unmet R&D Milestone target is achieved, DUPONT will pay GENENCOR at least *** of the next applicable R&D Milestone target for the next six (6) month period relative to the current applicable milestone. For such performance between *** of the performance standard, DUPONT will pay GENENCOR a linear interpolation between the previously described target and the current R&D Milestone target. [For purposes of illustrating the intent of this provision, an example is provided as Appendix 10.6 hereto.] 17 18 DuPont, Genencor Collaborative R&D Agreement
Rd Milestone Payments. Graphite will pay Stanford the following non-creditable, non-refundable milestone payments in connection with the first achievement by each Licensed Product of the respective milestones set forth below within thirty (30) days of achieving the corresponding milestone: Milestone Event Payment Upon [***] $ [***] Upon [***] $ [***] Upon [***] $ [***] Upon [***] $ [***] Upon [***] $ [***] Upon [***] $ [***] *“[***]” means (a) [***] OR (b) [***]. Each milestone payment in the table above shall be payable upon the first occurrence of the corresponding milestone event for each Licensed Product to achieve such milestone event; provided, however, that the milestone payments set forth in the table above shall not be payable with respect to a subsequent achievement of the same milestone event by a Licensed Product that is a replacement or backup product for another Licensed Product the development of which has been discontinued after achievement of such milestone event and for which Stanford has already received the respective milestone payment; provided, further, however, that the milestone payments set forth in the table above shall not be payable with respect to a subsequent achievement of the same milestone event by a Licensed Product (1) for a new indication that only differs from such prior indication by mode of delivery, line of therapy, stage of disease, population description (e.g., adult or pediatric) or additional therapies or (2) for a new indication where the underlying genetic defect being targeted or corrected by such Licensed Product is the same as a prior Licensed Product with respect to which such milestone payment has been paid (e.g., if the same gene locus is targeted for the same disease but with a more efficient DNA donor template).
Rd Milestone Payments. In consideration for the rights granted to CureVac under this Agreement, CureVac shall pay to myNEO the one-time, non-refundable, non-creditable research milestone payments set forth in this Section 8.4 (each a "R&D Milestone Payment").
Rd Milestone Payments